Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer
NCT06267144
·
clinicaltrials.gov ↗
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Lung Cancer
Interventions
DRUG:
Sintilimab plus chemotherapy
Sponsor
The First Hospital of Jilin University